Giulio natta biography of michael jackson
•
Asimov's Biographical Encyclopaedia of Information and Technology
•
Novel, soluble 3-heteroaryl-substituted tanshinone mimics attenuate the inflammatory response in murine macrophages
Introduction
Inflammation is a pivotal part of the non-specific defence mechanisms orchestrated by the innate immune system and represents a fundamental response to counteract biological, physical, and chemical threats1. One of the most potent stimuli triggering an inflammatory response in macrophages is LipoPolySaccharide (LPS), a ubiquitous component of Gram-negative bacterial membranes. LPS has strong macrophage-activating properties2 and is widely used in laboratory models to mimic inflammatory conditions. It induces the production of various inflammatory cytokines, including but not limited to IL-1β, IL6, and IL83. Such cytokines are tightly regulated at the post-transcriptional level by RNA Binding Proteins (RBPs) such as TTP4, HuR5 and TIAR6,7,8. The Human Antigen R (HuR or ELAVL1), a member of the ELAVL family, embodies the multifaceted role of RBPs, participating in diverse processes including organismal development9, cell growth10, inflammation11,12. HuR is ubiquitously expressed in human tissues and strongly conserved among mammals13. Structurally, HuR contains three RNA Recognition Motifs (RRMs), with RRM1 and RRM2 cooperativel
•
Published in final edited form as: Ophthalmology. 2020 Jul 24;127(12):1710–1718. doi: 10.1016/j.ophtha.2020.07.038
Abstract
Objective:
To evaluate the responsiveness of quality of life (QoL) metrics to ocular and systemic events in patients with non-infectious uveitis.
Design:
Cohort study using randomized controlled trial data.
Participants:
Patients with active or recently active intermediate, posterior, or panuveitis enrolled in the Multicenter Steroid Treatment (MUST) Trial and Follow-up Study.
Methods:
Data on the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25), EuroQol Questionnaire (EQ-5D), and the Short Form Survey Instrument (SF-36) were evaluated semi-annually during the first 3 years after randomization. The impact of ocular (e.g. changes in visual acuity, activity status, cataract surgery) and systemic events (e.g infections requiring treatment) on the 6-month changes in QoL was assessed for each metric using generalized estimating equations.
Main Outcome Measures:
The primary outcomes were the 6-month changes in vision-related (NEI-VFQ-25) and general health-related (EQ-5D index, SF-36 physical component score) QoL.
Results:
Changes in visual acuity (adjusted change [aΔ]: 2.70